Acadia's Rett Syndrome Drug Faces EU Regulatory Hurdle
Event summary
- Acadia Pharmaceuticals received a negative trend vote from the CHMP on its Marketing Authorization Application for trofinetide in Rett syndrome.
- The company plans to request a re-examination of the opinion following the formal CHMP vote in February 2026.
- Trofinetide is already approved in the U.S., Canada, and Israel but faces regulatory challenges in the EU.
- Acadia cites real-world data from over 1,000 patients globally to support trofinetide's benefits.
The big picture
Acadia's trofinetide faces a critical regulatory crossroads in the EU, where approval could significantly expand its market reach. The negative trend vote highlights the challenges of securing authorization for rare disease treatments across different regulatory frameworks. With over 1,000 patients already on treatment globally, Acadia’s ability to leverage real-world data may be key in overturning this initial setback.
What we're watching
- Regulatory Pathway
- Whether Acadia can successfully navigate the CHMP re-examination process to secure EU approval for trofinetide.
- Market Expansion
- The pace at which Acadia can expand trofinetide's availability beyond current approved markets if EU approval is delayed or denied.
- Competitive Positioning
- How this setback may impact Acadia’s strategic focus on rare disease treatments amid its broader pipeline development.